We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 135 results

  1. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study

    Background

    In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects,...

    Weijia **e, Jiaxin Li, ... Jian **a in Arthritis Research & Therapy
    Article Open access 14 August 2023

  2. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference

    Purpose of Review

    To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2024 Scientific Session of...

    Kartik Gupta, Bharat Rawlley, ... Salim S. Virani in Current Atherosclerosis Reports
    Article 03 June 2024

  3. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection

    Purpose of Review

    Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV)...

    Natalie Arnold, Wolfgang Koenig in Current Cardiology Reports
    Article Open access 10 September 2022

  4. Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1/2/17 cells, and clinical response of tumor necrosis factor inhibitor

    Aims

    Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates CD4 + T cell differentiation and inflammatory response, the latter ones mediate...

    Jialin Deng, Yongqian Jiang, ... Yuxiang Fu in Irish Journal of Medical Science (1971 -)
    Article 08 July 2023

  7. Vascular leak in sepsis: physiological basis and potential therapeutic advances

    Sepsis is a life-threatening condition characterised by endothelial barrier dysfunction and impairment of normal microcirculatory function, resulting...

    Ross R. McMullan, Daniel F. McAuley, ... Jonathan A. Silversides in Critical Care
    Article Open access 23 March 2024

  8. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

    Objective

    There is a large population of patients classified as complex higher-risk and indicated patients (CHIPs) in China with a poor prognosis. The...

    Zhi-li **, Tao He, ... Hai-rong Wang in Current Medical Science
    Article 27 September 2023

  9. Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention

    Background

    Current guidelines recommend a stepwise initiation of lipid-lowering therapy after percutaneous coronary interventions (PCI) in...

    Achim Leo Burger, Nora Beran, ... Kurt Huber in Wiener klinische Wochenschrift
    Article 24 October 2023

  10. Statin intolerance management: a systematic review

    Background

    Statin intolerance is a key barrier to the effective prevention of atherosclerotic cardiovascular disease (ASCVD). Experts do not agree on...

    Alejandra Meza-Contreras, Camila Wenczenovicz, ... Victor M. Montori in Endocrine
    Article 02 December 2022

  11. Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?

    Improvement in risk prediction of atherosclerotic cardiovascular disease (ASCVD) using information on the genetic predisposition at an individual...

    Natalie Arnold, Wolfgang Koenig in Cardiovascular Drugs and Therapy
    Article Open access 06 November 2020

  12. Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

    Background

    Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2...

    Meng-Meng Yu, **n Zhao, ... Meng-Su Zeng in Cardiovascular Diabetology
    Article Open access 22 May 2023

  14. LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight

    Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) have recently been identified to be closely related to the occurrence and development...

    Si-jie Yao, Tao-hua Lan, ... Wei Jiang in Chinese Journal of Integrative Medicine
    Article 07 November 2022

  15. A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia

    Despite the widespread use of statins and ezetimibe to decrease low-density lipoprotein cholesterol (LDL-C) levels and associated atherosclerotic...

    Stephanie Niman, Khyatiben Rana, ... Rebecca F. Goldfaden in American Journal of Cardiovascular Drugs
    Article 13 March 2020

  16. Hyperlipidemia and Cardiovascular Disease in People with Type 1 Diabetes: Review of Current Guidelines and Evidence

    Purpose of Review

    In this review, we discuss the prevalence of cardiovascular disease in people with type 1 diabetes. We outline key risk factors...

    Rehan Karmali, Joseph Sipko, ... Dennis Bruemmer in Current Cardiology Reports
    Article 13 April 2023

  17. Diabetischer Fuß mit Fokus auf Arterien

    Bodo Gutt in Info Diabetologie
    Article 01 September 2022

  18. Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice

    Background

    Obesity is associated with airway hyperresponsiveness and lung fibrosis, which may reduce the effectiveness of standard asthma treatment in...

    Lin Liang, Sook In Chung, ... Jung-Won Park in Respiratory Research
    Article Open access 18 May 2024

  19. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

    Background

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2...

    Sara Piccini, Giuseppe Favacchio, ... Marco Mirani in Cardiovascular Diabetology
    Article Open access 25 March 2023

  20. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke

    Background

    We investigated evolocumab’s real-world effectiveness and safety on a background of statin therapy in the acute phase of ischemic stroke...

    Ting Zhang, Ya**g Zhang, ... Wei Yue in Journal of Thrombosis and Thrombolysis
    Article 08 December 2023
Did you find what you were looking for? Share feedback.